Abstract
OBJECTIVE—To assess the health related quality of life and psychological wellbeing of patients with dilated cardiomyopathy, and relate these to clinical variables and psychological adjustment. DESIGN—Postal questionnaire survey of 99 adult patients with dilated cardiomyopathy, selected at random from a larger database (60.6% response rate). Assessments included the short form 36 (SF-36) health survey, the hospital anxiety and depression scales, the sleep problems index, and a measure of psychological adjustment to cardiomyopathy. RESULTS—Patients with dilated cardiomyopathy reported significant impairments in physical functioning, role limitations owing to physical and emotional problems, social functioning, mental health, perceptions of general health, sleep, and vitality. Anxiety and depression levels were higher than in population samples. Impairment in several domains of quality of life was associated with low shortening fraction, high left ventricular end diastolic diameter, and the presence of heart failure and mitral regurgitation. Patients with familial cardiomyopathy had less impairment in quality of life than those with non-familial disease. Psychological adjustment scores were associated with several aspects of quality of life and emotional wellbeing. In multivariate analysis, demographic and clinical variables accounted for 0.1-40.7% of the variance in different domains of quality of life, and psychological adjustment scores accounted for an additional 0.5-22.4% of variance. CONCLUSIONS—Patients with dilated cardiomyopathy experience pronounced restrictions in quality of life and psychological wellbeing. These limitations are only partly accounted for by symptoms and the severity of underlying disease. Patients may benefit from efforts to improve psychological adjustment to the condition. Keywords: dilated cardiomyopathy; quality of life; adjustment; wellbeing
Full Text
The Full Text of this article is available as a PDF (120.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cox S., O'Donoghue A. C., McKenna W. J., Steptoe A. Health related quality of life and psychological wellbeing in patients with hypertrophic cardiomyopathy. Heart. 1997 Aug;78(2):182–187. doi: 10.1136/hrt.78.2.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dec G. W., Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med. 1994 Dec 8;331(23):1564–1575. doi: 10.1056/NEJM199412083312307. [DOI] [PubMed] [Google Scholar]
- Guyatt G. H., Bombardier C., Tugwell P. X. Measuring disease-specific quality of life in clinical trials. CMAJ. 1986 Apr 15;134(8):889–895. [PMC free article] [PubMed] [Google Scholar]
- Herrmann C., Brand-Driehorst S., Kaminsky B., Leibing E., Staats H., Rüger U. Diagnostic groups and depressed mood as predictors of 22-month mortality in medical inpatients. Psychosom Med. 1998 Sep-Oct;60(5):570–577. doi: 10.1097/00006842-199809000-00011. [DOI] [PubMed] [Google Scholar]
- Herrmann C. International experiences with the Hospital Anxiety and Depression Scale--a review of validation data and clinical results. J Psychosom Res. 1997 Jan;42(1):17–41. doi: 10.1016/s0022-3999(96)00216-4. [DOI] [PubMed] [Google Scholar]
- Jenkinson C., Coulter A., Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 1993 May 29;306(6890):1437–1440. doi: 10.1136/bmj.306.6890.1437. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lisspers J., Nygren A., Söderman E. Hospital Anxiety and Depression Scale (HAD): some psychometric data for a Swedish sample. Acta Psychiatr Scand. 1997 Oct;96(4):281–286. doi: 10.1111/j.1600-0447.1997.tb10164.x. [DOI] [PubMed] [Google Scholar]
- Lyons R. A., Lo S. V., Littlepage B. N. Comparative health status of patients with 11 common illnesses in Wales. J Epidemiol Community Health. 1994 Aug;48(4):388–390. doi: 10.1136/jech.48.4.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Manolis A. G., Katsivas A. G., Lazaris E. E., Vassilopoulos C. V., Louvros N. E. Ventricular performance and quality of life in patients who underwent radiofrequency AV junction ablation and permanent pacemaker implantation due to medically refractory atrial tachyarrhythmias. J Interv Card Electrophysiol. 1998 Mar;2(1):71–76. doi: 10.1023/a:1009721008761. [DOI] [PubMed] [Google Scholar]
- McHorney C. A., Ware J. E., Jr, Raczek A. E. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993 Mar;31(3):247–263. doi: 10.1097/00005650-199303000-00006. [DOI] [PubMed] [Google Scholar]
- Musselman D. L., Evans D. L., Nemeroff C. B. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998 Jul;55(7):580–592. doi: 10.1001/archpsyc.55.7.580. [DOI] [PubMed] [Google Scholar]
- Richardson P., McKenna W., Bristow M., Maisch B., Mautner B., O'Connell J., Olsen E., Thiene G., Goodwin J., Gyarfas I. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996 Mar 1;93(5):841–842. doi: 10.1161/01.cir.93.5.841. [DOI] [PubMed] [Google Scholar]
- Tyni-Lenné R., Gordon A., Jansson E., Bermann G., Sylvén C. Skeletal muscle endurance training improves peripheral oxidative capacity, exercise tolerance, and health-related quality of life in women with chronic congestive heart failure secondary to either ischemic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol. 1997 Oct 15;80(8):1025–1029. doi: 10.1016/s0002-9149(97)00597-3. [DOI] [PubMed] [Google Scholar]
- Ware J. E., Jr, Sherbourne C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473–483. [PubMed] [Google Scholar]
- Wiklund I., Waagstein F., Swedberg K., Hjalmarsson A. Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Metoprolol in Dilated Cardiomyopathy trial. Cardiovasc Drugs Ther. 1996 Jul;10(3):361–368. doi: 10.1007/BF02627961. [DOI] [PubMed] [Google Scholar]